182 related articles for article (PubMed ID: 10942180)
1. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.
Carrillo JA; Christensen M; Ramos SI; Alm C; Dahl ML; Benitez J; Bertilsson L
Ther Drug Monit; 2000 Aug; 22(4):409-17. PubMed ID: 10942180
[TBL] [Abstract][Full Text] [Related]
2. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography.
Krul C; Hageman G
J Chromatogr B Biomed Sci Appl; 1998 May; 709(1):27-34. PubMed ID: 9653923
[TBL] [Abstract][Full Text] [Related]
3. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow.
Sinués B; Sáenz MA; Lanuza J; Bernal ML; Fanlo A; Juste JL; Mayayo E
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):159-66. PubMed ID: 10067814
[TBL] [Abstract][Full Text] [Related]
4. Influence of the urine flow rate on some caffeine metabolite ratios used to assess CYP1A2 activity.
Sinués B; Fanlo A; Bernal ML; Mayayo E; Soriano MA; Martínez-Ballarin E
Ther Drug Monit; 2002 Dec; 24(6):715-21. PubMed ID: 12451287
[TBL] [Abstract][Full Text] [Related]
5. Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities.
Hakooz NM
Curr Drug Metab; 2009 May; 10(4):329-38. PubMed ID: 19519341
[TBL] [Abstract][Full Text] [Related]
6. [Determination of caffeine metabolite for the evaluation of N-acetyltransferase, CYP1A2 and xanthine oxidase activities].
Lu JF; Yi T; Cao XM; Zhuo HT; Ling SS
Yao Xue Xue Bao; 1997 Nov; 32(11):813-8. PubMed ID: 11596199
[TBL] [Abstract][Full Text] [Related]
7. Caffeine metabolism before and after liver transplantation.
Bechtel YC; Lelouët H; Hrusovsky S; Brientini MP; Mantion G; Paintaud G; Miguet JP; Bechtel PR
Int J Clin Pharmacol Ther; 2001 Feb; 39(2):53-60. PubMed ID: 11270802
[TBL] [Abstract][Full Text] [Related]
8. Segregation analyses of four urinary caffeine metabolite ratios implicated in the determination of human acetylation phenotypes.
Vincent-Viry M; Pontes ZB; Gueguen R; Galteau MM; Siest G
Genet Epidemiol; 1994; 11(2):115-29. PubMed ID: 8013893
[TBL] [Abstract][Full Text] [Related]
9. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
Begas E; Kouvaras E; Tsakalof A; Papakosta S; Asprodini EK
Biomed Chromatogr; 2007 Feb; 21(2):190-200. PubMed ID: 17221922
[TBL] [Abstract][Full Text] [Related]
10. Caffeine metabolism in a group of 67 patients with primary biliary cirrhosis.
Lelouët H; Bechtel YC; Paintaud G; Brientini MP; Miguet JP; Bechtel PR
Int J Clin Pharmacol Ther; 2001 Jan; 39(1):25-32. PubMed ID: 11204934
[TBL] [Abstract][Full Text] [Related]
11. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements.
Tang BK; Zhou Y; Kadar D; Kalow W
Pharmacogenetics; 1994 Jun; 4(3):117-24. PubMed ID: 7920691
[TBL] [Abstract][Full Text] [Related]
12. Relationship between the severity of alcoholic liver cirrhosis and the metabolism of caffeine in 226 patients.
Bechtel YC; Haffen E; Lelouët H; Brientini MP; Paintaud G; Miguet JP; Bechtel PR
Int J Clin Pharmacol Ther; 2000 Oct; 38(10):467-75. PubMed ID: 11073287
[TBL] [Abstract][Full Text] [Related]
13. Correlation between assessment of cytochrome P450 1A2 activity and enzyme activity scores, and their relation to clozapine exposure.
Alarcan H; Cannet P; Camus V; Fond G; Zendjidjian X; Guilhaumou R; Quaranta S
Br J Clin Pharmacol; 2023 May; 89(5):1665-1671. PubMed ID: 36507652
[TBL] [Abstract][Full Text] [Related]
14. Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers.
Muscat JE; Pittman B; Kleinman W; Lazarus P; Stellman SD; Richie JP
Biochem Pharmacol; 2008 Oct; 76(7):929-37. PubMed ID: 18703023
[TBL] [Abstract][Full Text] [Related]
15. Dietary effects of Sideritis scardica "mountain tea" on human in vivo activities of xenobiotic metabolizing enzymes in healthy subjects.
Begas E; Kilindris T; Kouvaras E; Tsioutsioumi A; Kouretas D; Asprodini EK
Food Chem Toxicol; 2018 Dec; 122():38-48. PubMed ID: 30266316
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 2A6 Phenotyping Using Dietary Caffeine Salivary Metabolite Ratios and Genotyping Using Blood on Storage Cards in Non-smoking Japanese Volunteers.
Murayama N; Shimizu M; Kobayashi K; Kishimoto I; Yamazaki H
Drug Metab Lett; 2017; 10(4):240-243. PubMed ID: 27842485
[TBL] [Abstract][Full Text] [Related]
17. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities.
Relling MV; Lin JS; Ayers GD; Evans WE
Clin Pharmacol Ther; 1992 Dec; 52(6):643-58. PubMed ID: 1458773
[TBL] [Abstract][Full Text] [Related]
18. Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities.
Fuchs P; Haefeli WE; Ledermann HR; Wenk M
Eur J Clin Pharmacol; 1999 Jan; 54(11):869-76. PubMed ID: 10027663
[TBL] [Abstract][Full Text] [Related]
19. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction.
Abraham K; Geusau A; Tosun Y; Helge H; Bauer S; Brockmöller J
Clin Pharmacol Ther; 2002 Aug; 72(2):163-74. PubMed ID: 12189363
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms of CYP1A2 and CYP2A6 activity: phenotypes and the effect of age and sex in a Nigerian population.
Adehin A; Bolaji OO
Drug Metab Pers Ther; 2015 Sep; 30(3):203-10. PubMed ID: 26098700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
